Form 4: Septerna CPO Executes Stock Option Exercise and Sale

Chief People Officer Samira Shaikhly exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Chief People Officer Samira Shaikhly exercised options for a total of 5,935 shares of common stock.
• The exercise prices for these options were $1.55 and $2.76 per share.
• Following the exercise, the reporting person sold 5,935 shares in multiple transactions at weighted average prices ranging from $27.78 to $29.66.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive equity management.

Positives

• The executive maintains a remaining beneficial ownership of 793 shares of common stock.
• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a member of the executive leadership team.

Risks

• Future share price volatility could impact the value of remaining unvested stock options.
• Continued reliance on Rule 10b5-1 plans for liquidity may signal ongoing divestment by insiders.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via Rule 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and tax obligations, and does not necessarily reflect a change in sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a common governance practice among US-listed biotech firms to avoid allegations of insider trading.
• The exercise and sale behavior is consistent with typical executive compensation realization patterns for growth-stage pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were executed under a pre-planned 10b5-1 arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Septerna, SEPN, Insider Trading, Form 4, Stock Options, Executive Compensation